DelveInsight's "Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Intratumoral Cancer Therapies market size and shares analysis in the seven major markets (7MM).
The report also covers emerging therapies, current treatment practices, Intratumoral Cancer Therapies Market Shares of the individual therapies, a detailed current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.
Geographies Covered
The report analyses the Intratumoral Cancer Therapies Market trends and developments in the seven major markets (i.e. the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
Intratumoral Cancer Therapies: An Overview
Intratumoral therapies. Intratumoral (intralesional) administration of immunotherapeutics is a promising way to target local tumor immunity barriers directly. Even though intratumoral therapy most often refers to direct injection into the tumors, it can also refer to any therapy provided in close anatomical proximity to a tumor with the goal of direct uptake by tumors. There are different categories of intratumoral therapies: cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules.
Intratumoral Cancer Therapies: Facts & Findings
- As per DelveInsight, among selected nine major indications for the Intratumoral therapies, Nonmelanoma skin cancer (NMSC) contributed to the highest number of cases in the 7MM. The total number of NMSC in the 7MM was 774,926 in 2020. The United States, with 524,737 NMSC incident cases, had the highest number of NMSC incident cases among the seven major markets.
- In 2020, the total Indication-wise eligible cases were 736,184 cases in the 7MM, whereas, Japan accounted for 126,718 Indication-wise eligible cases in the same year which are projected to increase during the study period.
- In the 7MM, the total treated cases of all selected cancer types in neoadjuvant/adjuvant setting and first-line were 1,065,771, and 736,184 in 2020, which are expected to grow in the coming years.
Intratumoral Cancer Therapies Market
The Intratumoral cancer therapies market size in the 7MM is expected to grow in the coming years. According to the estimates, the highest market size of Intratumoral cancer therapies is found in the United States.
The United States Market Outlook
In the United States, the Intratumoral Cancer Therapies Market Size is expected to increase at a CAGR of 42.0% during the study period.
Intratumoral Cancer Therapies Market Analysis
The Intratumoral Cancer Therapies market analysis section of the report helps to understand the current and forecasted Intratumoral Cancer Therapies Market Trends and Growth by evaluating the impact of current therapies on the market, unmet needs, drivers, and barriers.
The report gives complete detail of Intratumoral Cancer Therapies Market Size and Shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Intratumoral Cancer Therapies Epidemiology Forecast
The epidemiology section covers detailed insights about the patient pool for every seven major countries. It helps to recognize the causes of current and forecasted Intratumoral Cancer Therapies Epidemiology Trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Intratumoral Cancer Therapies Pipeline Insights
The Intratumoral Cancer Therapies Pipeline and Drugs Uptake section focus on the rate of uptake of the market therapies as well as the therapies expected to get launch in the coming years. The analysis covers the Intratumoral Cancer Therapies Market uptake by drugs, patient uptake by therapies, and drug sales.
Intratumoral Cancer Therapies Pipeline Development Activities and key companies
Globally, some of the key companies are actively working in the Intratumoral Cancer Therapies Market. The launch of the therapies is expected to change the Cancer treatment dynamics in the coming.
Some of the key companies in the Intratumoral Cancer Therapies Market include:
- Checkmate Pharmaceuticals
- OncoSec Medical Incorporated
- Merck
- Istari Oncology
- Replimune/ Regeneron
- Philogen
- Exicure
- Sirnaomics
- Nanobiotix
- Intensity Therapeutics
- NanOlogy
- Lokon Pharma
- Immunicum
- DNAtrix
- Treovir
- Idera Pharmaceuticals
- Immunovative Therapies
And many others
Some of the leading Intratumoral Cancer Therapies Covered in the report include:
- G207
- Tilsotolimod (IMO-2125)
- AlloStim
- Vidutolimod (CMP-001)
- Tavo (tavokinogene telseplasmid)
- CAVATAK (V937; CVA21)
- PVSRIPO (PVS-RIPO)
- RP1 (vusolimogene oderparepvec)
- Daromun (Nidlegy)
- Cavrotolimod (AST-008)
- Cotsiranib (STP705)
- Intuvax (Ilixadencel)
- Hensify (NBTXR3/ PEP503)
- INT230-6 (Cisplatin/vinblastine)
- NanoPac (LSAM paclitaxel)
- Delolimogene mupadenorepvec (LOAd703)
- Tasadenoturev (DNX-2401)
And many more.
Report Assessment
- Unmet Needs
- Market Attractiveness
- Current Treatment Practices
- Intratumoral Cancer Therapies Market Drivers
- Intratumoral Cancer Therapies Market Barriers
- Intratumoral Cancer Therapies Pipeline Product
For more details, visit: Intratumoral Cancer Therapies Market Share